[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100651754":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":30,"responsibleParty":47,"collaborators":19,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":51,"sex":57,"minAge":58,"maxAge":19,"enrollmentInfo":59,"targetDuration":19,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":79,"whyStopped":19,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"University Hospital, Toulouse","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Nuclear imaging (PSMA PET)","EXPERIMENTAL","Nuclear imaging (PSMA PET) with intravenous injection of a radiotracer one year after treatment (focal therapy)",[13],"Drug: Nuclear imaging (PSMA PET) with intravenous injection of a radiotracer one year after treatment (focal therapy)",[15],{"type":16,"name":11,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Nuclear imaging (PSMA PET) with intravenous injection of a radiotracer p one year after treatment, multiparametric prostate MRI in accordance with current recommendations, follow-up prostate biopsy as part of routine care.",[9],null,[21,27],{"name":22,"role":23,"phone":24,"phoneExt":25,"email":26},"Anne-Sophie BAJEOT, MD-PH","CONTACT","05 61 32 35 49","+33","bajeot.as@chu-toulouse.fr",{"name":28,"role":23,"phone":19,"phoneExt":19,"email":29},"Jeremy MERCIER, MD-PH","Mercier.j@chu-toulouse.fr",[31],{"facility":32,"status":19,"city":33,"state":19,"zip":19,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"University Hospital of Toulouse","Toulouse","France","FR",{"type":37,"coordinates":38},"Point",[39,40],1.44367,43.60426,{"lat":40,"lon":39},[43,44,45],{"name":22,"role":23,"phone":24,"phoneExt":25,"email":26},{"name":28,"role":23,"phone":19,"phoneExt":19,"email":29},{"name":22,"role":46,"phone":19,"phoneExt":19,"email":19},"PRINCIPAL_INVESTIGATOR",{"type":48,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100651754","phase-4-analysis-of-the-performance-of-psma-emission-tomography-in-patients-with-prostate-cancer-treated-with-hifu-100651754",false,"NCT07766122","Analysis of the Performance of PSMA Emission Tomography in Patients With Prostate Cancer Treated With HIFU","Pilot Study Evaluating PSMA Positron Emission Tomography for Monitoring Clinically Significant Prostate Cancer After Focal HIFU Treatment","ECETEP","Inclusion Criteria:\n\n* Patient with prostate cancer\n* Age ≥ 70 years (HAS 2023)\n* Life expectancy \\> 5 years\n* Clinical stage Clinical stage T1c - T2a PSA \\\u003C 20 ng\u002Fml Biopsy :ISUP 2 unilateral on a maximum of 2 contiguous sextants with or without ipsilateral or contralateral focus ISUP1 single focus or multiple foci if only one ISUP 2 focus on targeted biopsy\n* Imaging Single lesion PIRADS 3 or 4 or 5 Volume of prostate gland \\\u003C 150 ml\n* Enrolled in a social security scheme\n* Signature of consent\n\nExclusion Criteria:\n\n* Evidence of extra-prostatic extension or invasion of the seminal vesicles.\n* Any condition that, in the judgement of the investigators, would interfere with the subject's ability to\n* provide informed consent, comply with study instructions, expose the subject to increased risk, or interfere with the interpretation of study results.\n* Patients deprived of their liberty or under legal protection (curatorship and guardianship, safeguard of justice)\n* Hypersensitivity to the active substances or to any of the excipients\n* Conditions contraindicating magnetic resonance imaging (MRI), such as the presence of internal metallic devices.\n* Chronic kidney disease with an eGFR ≤ 60 mL\u002Fmin\n* Liver failure","MALE","70 Years",{"count":60,"type":61},30,"ESTIMATED","INTERVENTIONAL",[64],"PHASE4","There would appear to be a strong interest in functional nuclear imaging for assessing the response to focal PaC treatment. Investigator team hypothesise that the diagnostic performance of PSMA PET is noninferior to that of MRI in detecting clinically significant recurrent PaC after treatment with HIFU. The main objective was to evaluate the diagnostic performance of PSMA PET compared with MRI with reference to the gold standard of prostate biopsy one year after HIFU.",[67,68],"Prostate Cancer - Recurrent","Prostate Cancer (Diagnosis)",[70,71,72,73,74,75,76,77,78],"prostate cancer","focal treatment","focal therapy","high-intensity focused ultrasound (HIFU)","PET PSMA","prostate MRI","recurrence","post-treatment follow-up","functional nuclear imaging","NOT_YET_RECRUITING","2026-08-10",{"date":82,"type":83},"2026-08-14","ACTUAL",{"date":85,"type":61},"2026-10",{"date":87,"type":61},"2028-10",{"name":5,"class":6},1]